Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
TipRanks on MSN

Genprex reports positive preclinical results for GPX-002 diabetes therapy

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions The latest update is out from Genprex ( (GNPX) ). On January 6, 2026, Genprex reported positive preliminary ...
GEN

Immunotherapy-Related Diabetes Linked to New Immune Cell Targeted by JAK Inhibitors in Mouse Model

A team of researchers at UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and potentially reverse, immune checkpoint inhibitor (ICI)–induced type I ...
Healio

Prediction model compares lifestyle intervention, metformin for preventing type 2 diabetes

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A risk prediction model assesses seven variables to ...
Medscape

Turning the Tide in Type 2 Diabetes: Evidence-Based Pathways to Remission

New evidence shows that remission in type 2 diabetes is attainable through weight loss, surgery, pharmacotherapy, and intensive lifestyle change.

Genprex, Inc.: Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human Primates GPX-002 Rejuvenated Exhausted ...